The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•11 February 2026•

1 min read

Evercore ISI Raises Quest Diagnostics (DGX) Target to $220; GuruFocus Sees Downside

Evercore ISI Group has increased its price target for Quest Diagnostics (DGX) to $220, up from the previous $190. This adjustment reflects a significant 15.79% rise, signaling the firm's confidence in the company's growth prospects. Despite this optimistic revision, Evercore ISI maintained an "In-Line" rating for the stock. Countering this view, GuruFocus estimates a potential downside for DGX based on its GF Value fair value calculation. This divergence highlights a mixed outlook, where strong analyst confidence is tempered by valuation concerns. Investors will likely weigh both the upward target revision and the potential valuation risks when assessing DGX.